THE Q-TRAK SUBCUTANEOUS ELECTRODE
Report
- Report Number
- 2124215-2025-41890
- Event Type
- Malfunction
- Date Received
- June 25, 2025
- Date of Event
- April 1, 2010
- Report Date
- June 25, 2025
- Manufacturer
- BOSTON SCIENTIFIC CORPORATION
- Product Code
- LWS
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GA, US
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
M. F. EL-CHAMI, B. HARBIEH, M. LEVY, A. R. LEON, AND F. M. MERCHANT, CLINICAL AND ELECTROCARDIOGRAPHIC PREDICTORS OF T WAVE OVERSENSING IN PATIENTS WITH SUBCUTANEOUS ICD, JOURNAL OF ARRHYTHMIA 32 (2016): 181-185.
IT WAS REPORTED PER ARTICLE OF INTEREST LITERATURE REVIEW THAT THE AUTHORS SOUGHT IDENTIFY CLINICAL AND ELECTROCARDIOGRAPHIC PREDICTORS OF T-WAVE OVERSENSING (TWOS) IN A COHORT OF PATIENTS UNDERGOING SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (S-ICD). THEY RETROSPECTIVELY IDENTIFIED ALL PATIENTS WHO UNDERWENT S-ICD IMPLANTATION (CAMERON HEALTH MODEL NUMBER 1010 SQ-RX, WITH A SUBCUTANEOUS LEAD-CAMERON HEALTH MODEL 3010) AT THEIR INSTITUTION FROM APRIL 2010 TO JANUARY 2015. NINETY-TWO PATIENTS UNDERWENT S-ICD IMPLANTATION. DURING A MEAN FOLLOW-UP OF 13.1 MONTHS, SIX PATIENTS HAD TWOS RESULTING IN INAPPROPRIATE SHOCKS. IN THE GROUP WITHOUT TWOS, TWO PATIENTS EXPERIENCED INAPPROPRIATE SHOCKS FOR NON-TWOS ETIOLOGIES: ONE FOR SUPRAVENTRICULAR RHYTHM AND ONE FOR ELECTROMAGNETIC INTERFERENCE. CASE 4: A 49-YEAR-OLD MAN WITH ISCHEMIC CARDIOMYOPATHY UNDERWENT S-ICD IMPLANTATION FOR PRIMARY PREVENTION. TWENTY MONTHS LATER HE PRESENTED WITH AN INAPPROPRIATE SHOCK FOR TWOS IN THE SETTING OF SINUS TACHYCARDIA DURING AN ALTERCATION. THE SENSING VECTOR WAS CHANGED FROM PRIMARY TO SECONDARY WITHOUT FURTHER TWOS IN THE FOLLOWING 37 MONTHS. THE S-ICD SYSTEM REMAINS IN SERVICE. NO ADVERSE PATIENT EFFECTS WERE REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2399134 | THE Q-TRAK SUBCUTANEOUS ELECTRODE | IMPLANTABLE LEAD | LWS | BOSTON SCIENTIFIC CORPORATION | 3010 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 49 YR | Male |